Product NewsIONTAS Identifies Novel SARS-CoV-2 Neutralizing Antibodiesby IONTASPotent antibodies shown to retain binding to major COVID-19-causing “South African” variant
NewsIONTAS and FairJourney Biologics Enter Antibody Discovery Agreement with Quell Therapeuticsby IONTAS,FairJourney BiologicsDiverse panel of novel target binders from IONTAS / FJB will be used to uncover functional antibodies to advance Quell’s engineered Treg cell therapy pipeline
NewsIONTAS and Adaptate Biotherapeutics Collaborate to Identify Optimized Antibodies for Novel Cancer Targetsby IONTAS,Adaptate BiotherapeuticsThe agreement is to generate and optimize antibodies for novel immuno-oncology targets
NewsIONTAS Signs Collaboration Agreement with LG Chem to Identify Therapeutic Oncology Leadsby IONTASIONTAS Limited announced it has signed a collaboration agreement with Korean-based LG Chem, Ltd.
Iontas Awarded $737K from Innovate UK to Develop Therapies for Chronic Pain Managementby IONTASFunding will be used to further develop IONTAS’ ion-channel targeting KnotBody antibody platform to block pain transmission via Nav1.7
NewsIONTAS and aTen Therapeutics Announce Collaboration to Discover Therapeutic Oncology Leadsby aTen Therapeutics,IONTASIONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by aTen
NewsIONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE Antibodies for Cancer Targetsby IONTASNew project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study